Refine
Year of publication
Document Type
- Article (51)
Has Fulltext
- yes (51)
Is part of the Bibliography
- no (51)
Keywords
- Acute myeloid leukemia (5)
- AML (3)
- Chemotherapy (3)
- Induction chemotherapy (3)
- Cancer (2)
- HSCT (2)
- Intensive care treatment (2)
- Multivariate analysis (2)
- Neutropenia (2)
- Oncology (2)
- Survival (2)
- Toxicity (2)
- acute myeloid leukaemia (2)
- acute myeloid leukemia (2)
- autologous stem cell transplantation (2)
- chemotherapy (2)
- induction chemotherapy (2)
- leukemia (2)
- multiple myeloma (2)
- proteomics (2)
- ASCT (1)
- Acute Myeloid Leukemia (1)
- Acute kidney failure (1)
- Acute myeloid leukaemia (1)
- Anticoagulation (1)
- BCOR (1)
- BCORL1 (1)
- BEZ235 (1)
- Becton Dickinson (1)
- Biochemie (1)
- Biomarker (1)
- Biomarkers (1)
- Bloodstream infection (1)
- Bloodstream infections (1)
- Body mass index (1)
- Bone marrow (1)
- Bone marrow aspiration (1)
- CBC (1)
- CDI (1)
- CHIP (1)
- Cancer chemotherapy (1)
- Cancer risk factors (1)
- Cancer treatment (1)
- Cell signalling (1)
- Clinical Trials and Observations (1)
- Cluster (1)
- Colorectal cancer (1)
- Conventional Chemotherapeutic (1)
- Cytogenetics (1)
- Death rates (1)
- Deletion mutation (1)
- Deutschland (1)
- ET (1)
- Echtzeit-NMR-Spektroskopie (1)
- Enterobacteriaceae (1)
- Fevers (1)
- Fluid overload (1)
- G-quadruplex binders (1)
- Germany (1)
- Gram negative bacteria (1)
- H1N1 (1)
- Haematopoietic stem cells (1)
- Hemagglutination inhibition assay (1)
- Hematology (1)
- Hematopoietic stem cell transplant (1)
- Hematopoietic stem cell transplantation (1)
- Hospitals (1)
- Intensive care units (1)
- Iron Overload (1)
- Iron chelation (1)
- Issue 96 (1)
- Karyotypes (1)
- Krebsforschung (1)
- Long-term follow-up (1)
- Lymphomas (1)
- MPN (1)
- MPN-U (1)
- Major bleeding (1)
- Medicine (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Molecularly targeted therapy (1)
- Myelodysplastic syndrome (1)
- Myeloid Neoplasia (1)
- NK cells (1)
- NKG2A blocking (1)
- Obesity (1)
- Oncogenes (1)
- PI3K/mTor inhibition (1)
- PMF (1)
- PV (1)
- Peripheral blood smears (1)
- Personalisierte Medizin (1)
- Phase I clinical trial (1)
- Phase I trials (1)
- Proteomics (1)
- RBC (1)
- Refractory ALL (1)
- Refractory AML (1)
- Relapse surveillance (1)
- SARS-CoV-2 (1)
- SARS-CoV-2-specific T cells (1)
- SW480 Cell (1)
- Self-renewal (1)
- Sequelae (1)
- Sphere Formation Assay (1)
- Stem-cell therapies (1)
- Stenotrophomonas maltophilia (1)
- Stoffwechsel (1)
- TBI (1)
- Thromboembolism (1)
- Thrombosis (1)
- Tumorsphere Formation (1)
- Vacuoles (1)
- Zellstudien (1)
- adoptive cell therapy (1)
- age (1)
- antifungal management (1)
- antifungal prophylaxis (1)
- asparaginyl endopepdidase (AEP) (1)
- biological chemistry (1)
- bleeding (1)
- blood cell mutations (1)
- c-Myc (1)
- cell studies (1)
- checkpoint inhibition (1)
- chronic hypoxia (1)
- chronic myeloid leukemia (1)
- clonal dominance (1)
- clonal haematopoiesis (1)
- clonal hematopoiesis (1)
- costs (1)
- cytarabine dose (1)
- elderly (1)
- formalin-fixed and paraffin-embedded tissue (FFPE) (1)
- glycolysis (1)
- head-and-neck cancer (1)
- heart failure (1)
- hematopoietic stem cells (1)
- hematopoietic stress (1)
- intracranial hemorrhage (1)
- laser-capture microdissection (1)
- legumain (1)
- loss-of-function (1)
- lung cancer (1)
- metabolic reprogramming (1)
- metabolism (1)
- metastasis (1)
- miRNAs (1)
- microenvironment (1)
- multisite cooperation (1)
- myelodysplastic syndrome (1)
- nitroindoles (1)
- oncogene promoters (1)
- personalized medicine (1)
- personalized oncology (1)
- platelet substitution (1)
- posaconazole (1)
- quantitative mass spectrometry (1)
- radical oxygen species (1)
- reactive oxygen species (1)
- real-time NMR spectroscopy (1)
- research consortium (1)
- risk stratification (1)
- solid tumors (1)
- somatic mutations (1)
- spike-in SILAC (1)
- structure-activity relationships (1)
- survival (1)
- transfusion (1)
- translational cancer research (1)
- tyrosine kinase inhibitors. (1)
- vaccination (1)
Institute
- Medizin (48)
- Biochemie und Chemie (3)
- Präsidium (3)
- Sonderforschungsbereiche / Forschungskollegs (3)
- Biochemie, Chemie und Pharmazie (2)
- Exzellenzcluster Herz-Lungen-System (2)
- Exzellenzcluster Makromolekulare Komplexe (2)
- Georg-Speyer-Haus (2)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (2)
- Biowissenschaften (1)
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases leading to an insufficient formation of functional blood cells. Disease-immanent factors as insufficient erythropoiesis and treatment-related factors as recurrent treatment with red blood cell transfusions frequently lead to systemic iron overload in MDS and AML patients. In addition, alterations of function and expression of proteins associated with iron metabolism might are increasingly recognized to be pathogenetic factors and potential vulnerabilities of these diseases. Iron is known to be involved in multiple intracellular and extracellular processes. It is essential for cell metabolism as well as for cell proliferation and closely linked to the formation of reactive oxygen species. Therefore, iron can influence the course of clonal myeloid disorders, the leukemic environment and the occurrence as well as the defense of infections. Imbalances of iron homeostasis may induce cell death of normal but also of malignant cells. New potential treatment strategies utilizing the importance of the iron homeostasis include iron chelation, modulation of proteins involved in iron metabolism, induction of leukemic cell death via ferroptosis and exploitation of iron proteins for the delivery of antileukemic drugs.
Here, we provide a summary of some of the latest findings about the function, the prognostic impact and potential treatment strategies of iron in patients with MDS and AML.